Home > Haematology > EHA 2019 > Myeloid Malignancies > Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

In a phase 1 trial of asciminib in combination with imatinib in heavily pre-treated patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), 60% (9/15) of participants achieved a molecular response rate <1% in the asciminib+imatinib arm [1].

Asciminib binds the myristate-binding pocket of the Bcr-Abl kinase domain. In the current study, presented by Prof. Jorge Cortes (University of Texas MD Anderson Cancer Center, USA), patients ≥18 years of age had a confirmed diagnosis of CML-CP. Patients had to be on a minimum of 2 years treatment with imatinib first line for CML-CP, BCR-ABL1 levels had to be >0.01% International Scale (IS) and ≤ 1% IS at the time of study entry as confirmed with a central assessment at screening and must not have achieved molecular response (MR)4 IS at any time during prior imatinib treatment.

The primary outcome was MR<...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on